Abstract
The pharmacokinetic characteristics of everolimus are described, and the interaction effects of concomitant antiseizure medications on everolimus in terms of its pharmacokinetics and pharmacodynamics are highlighted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ebrahim-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex. Pediatr Neurol. 2020;105:59–61.
Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol interacts significantly with everolimus – report of a patient with tuberous sclerosis complex. Neuropediatrics. 2019;50:400–3.
Bialer M, Johannessen SI, Levy RH, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XII). Epiepsia. 2017;58:181–221.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patsalos, P.N. (2022). Everolimus. In: Antiseizure Medication Interactions. Springer, Cham. https://doi.org/10.1007/978-3-030-82790-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-82790-8_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82789-2
Online ISBN: 978-3-030-82790-8
eBook Packages: MedicineMedicine (R0)